Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: High-Intensity Interval Training (HIIT), Moderate-Intensity Continuous Training (MICT).
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to examine the feasibility and effects of 12-week exercise training at different intensities among individuals with advanced lung cancer receiving immune checkpoint inhibitors. The names of the study interventions involved in this study are: * High-intensity interval training (HIIT) * Moderate-intensity continuous training (MICT) * Usual care (UC)
Detailed description
This single-center, three-armed, pilot randomized controlled research study will assess feasibility and compare immune activities, cardiorespiratory fitness, physical function, and immunotherapy-related adverse events, and patient-reported outcomes between three groups - high-intensity exercise, moderate-intensity exercise, and usual care.
Participants in this study will be randomly assigned to one of three groups:
* High-intensity interval training (HIIT) * Moderate-intensity continuous training (MICT) * Usual care (UC) The HIIT and the MICT groups will receive virtually supervised home-based exercise training three sessions per week for 12 weeks. The UC group will be asked not to change their baseline exercise behavior and will be offered to receive one of the exercise programs at the end of the initial 12 weeks.
Interventions
- Behavioral High-Intensity Interval Training (HIIT)
Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion. - Behavioral Moderate-Intensity Continuous Training (MICT)
Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
Primary outcome measures
- Proportion of Participants completing the exercise intervention sessions [Time frame: Up to 14 weeks]
Secondary outcome measures (9)
- Neutrophil-lymphocyte ratio (NLR) [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Cardiopulmonary Fitness [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Muscular Strength [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Short Physical Performance Battery [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Patient Reported Outcomes - Health-related quality of life [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Patient Reported Outcomes - Lung-cancer related quality of life [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Patient Reported Outcomes - Immunotherapy Symptoms [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Patient Reported Outcomes - Anxiety and Depression [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
- Patient Reported Outcomes - Sleep Quality [Time frame: Baseline (Week 1) and post-intervention (Week 14)]
Eligibility criteria
Inclusion criteria
- Age ≥18 years.
- Histologically diagnosed with non-small cell lung cancer (NSCLC).
- Having been receiving immunotherapy for at least one month with a plan to continue for at least 12 weeks prospectively at the time of recruitment.
- Medical clearance to perform exercise intervention and testing by their treating oncologist.
- No uncontrolled medical conditions that could be exacerbated with exercise (e.g., uncontrolled hypertension or diabetes).
- Ability to communicate and complete written forms in English.
- Participate in less than or equal to 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month.
- Ability to understand and the willingness to sign informed consent prior to any study-related procedures.
- Willing to travel to DFCI for necessary data collection.
Exclusion criteria
- Participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described exercise intervention, where additional exercise done regularly will contaminate the intervention outcomes.
- Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded.
- Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
- Development of second malignancy (except for basal cell carcinoma or squamous cell carcinoma of the skin) that requires concurrent treatment, which would interfere with this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- Dana-Farber Cancer Institute — Boston
Identifiers
NCT: NCT06026111 · 23-247